Qiagen N.V. (0RLT.IL)

43,54 0,00 (0,00%) Börsenschluss: 05:27PM BST

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 6.100

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Thierry Bernard	CEO, MD & Member of Management Board	2,67M	N/A	1965
Dr. Roland Sackers	CFO, MD & Member of Management Board	1,33M	N/A	1969
Mr. Antonio Santos	Sr. VP & Head of Global Operations	N/A	N/A	N/A
Mr. John Gilardi	VP of Corp. Communications & Investor Relations	N/A	N/A	N/A
Ms. Stephany Foster	Sr. VP & Head of HR	N/A	N/A	1979
Dr. Thomas Schweins	Sr. VP of Life Science Bus. Area	N/A	N/A	N/A
Dr. Thomas Theuringer	Sr. Director & Head of External Communications	N/A	N/A	N/A
Mr. Jean-Pascal Viola	Sr. VP & Head of Molecular Diagnostics Bus. Area	N/A	N/A	N/A
Dr. Jonathan G. Sheldon Ph.D.	Sr. VP of Qiagen Digital Insights Bus. Area	N/A	N/A	1972
Mr. Thomas Neidert	VP of Global Treasury	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Corporate Governance

Qiagen N.V.s ISS Governance QualityScore, Stand 1. Oktober 2023, lautet 2. Die grundlegenden Scores sind Audit: 1, Vorstand: 3, Shareholderrechte: 5, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.